SG10201802789VA - Use of a vegf antagonist to treat angiogenic eye disorders - Google Patents

Use of a vegf antagonist to treat angiogenic eye disorders

Info

Publication number
SG10201802789VA
SG10201802789VA SG10201802789VA SG10201802789VA SG10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA SG 10201802789V A SG10201802789V A SG 10201802789VA
Authority
SG
Singapore
Prior art keywords
vegf antagonist
eye disorders
angiogenic eye
treat angiogenic
treat
Prior art date
Application number
SG10201802789VA
Other languages
English (en)
Inventor
D Yancopoulos George
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45507924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201802789V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201802789VA publication Critical patent/SG10201802789VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG10201802789VA 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders SG10201802789VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161432245P 2011-01-13 2011-01-13
US201161434836P 2011-01-21 2011-01-21
US201161561957P 2011-11-21 2011-11-21

Publications (1)

Publication Number Publication Date
SG10201802789VA true SG10201802789VA (en) 2018-05-30

Family

ID=45507924

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201802789VA SG10201802789VA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG2013048798A SG191334A1 (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG10201509193UA SG10201509193UA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG10202111177VA SG10202111177VA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG2013048798A SG191334A1 (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG10201509193UA SG10201509193UA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders
SG10202111177VA SG10202111177VA (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders

Country Status (13)

Country Link
US (13) US9254338B2 (ko)
EP (4) EP4360709A3 (ko)
JP (5) JP2014503555A (ko)
KR (6) KR20210030510A (ko)
CN (1) CN103533950A (ko)
AU (4) AU2012205599B2 (ko)
BR (1) BR112013017752A8 (ko)
CA (1) CA2824422A1 (ko)
HK (1) HK1244693A1 (ko)
IL (3) IL295359A (ko)
MX (2) MX349901B (ko)
SG (4) SG10201802789VA (ko)
WO (1) WO2012097019A1 (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
EP4360709A3 (en) 2011-01-13 2024-07-03 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CA2970315C (en) * 2014-12-11 2023-08-22 Bayer Healthcare Llc Use of anti-vegf agents to treat lesions in macular degeneration patients
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
EP3261630A4 (en) * 2015-02-26 2018-10-10 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017046140A1 (en) * 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017091473A1 (en) 2015-11-24 2017-06-01 Indiana University Research & Technology Corporation Composition for blocking angiogenesis
CA3007276C (en) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP6944958B2 (ja) * 2016-05-25 2021-10-06 参天製薬株式会社 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
US20190388522A1 (en) * 2017-01-25 2019-12-26 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
KR20200125926A (ko) * 2017-11-16 2020-11-05 이베릭 바이오, 인크. 특발성 결절 맥락막 혈관병증(ipcv)을 치료 또는 예방하는 방법
EP3716992B1 (en) * 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
US20210017266A1 (en) * 2018-03-16 2021-01-21 Novartis Ag Methods for treating ocular diseases
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
JP2022547681A (ja) * 2019-09-12 2022-11-15 ルピン・リミテッド 眼科使用のためのｖｅｇｆ阻害剤の改変された投薬
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
TW202128744A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法
MX2022006751A (es) 2019-12-06 2022-08-19 Regeneron Pharma Minitrampas de vegf y metodos de uso de las mismas.
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
AU2021287906A1 (en) * 2020-06-11 2022-12-15 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
WO2022186335A1 (ja) * 2021-03-03 2022-09-09 学校法人自治医科大学 副作用の予測方法およびそのための装置
EP4323399A1 (en) * 2021-04-14 2024-02-21 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230302085A1 (en) * 2021-05-17 2023-09-28 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
ATE293164T1 (de) * 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
PT1441589E (pt) 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
WO2003039404A2 (en) 2001-11-09 2003-05-15 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
JP2003309411A (ja) 2002-04-17 2003-10-31 Alps Electric Co Ltd 複合アンテナ
US7300563B2 (en) 2003-02-07 2007-11-27 Pavco, Inc. Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths
PL1608685T3 (pl) 2003-03-28 2007-07-31 Regeneron Pharma Antagoniści VEGF do leczenia cukrzycy
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
WO2004103159A2 (en) 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
WO2004106378A2 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
EP1753442A2 (en) 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
AU2005265071A1 (en) 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
US7378095B2 (en) 2004-07-30 2008-05-27 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
EP2311433A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
AU2006214658A1 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
PL1861116T3 (pl) 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
AU2007323925A1 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
EP4360709A3 (en) * 2011-01-13 2024-07-03 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
WO2015110067A1 (zh) 2014-01-25 2015-07-30 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其用途
TWI761959B (zh) 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
EP3716992B1 (en) 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders

Also Published As

Publication number Publication date
US9669069B2 (en) 2017-06-06
HK1244693A1 (zh) 2018-08-17
US20210308217A1 (en) 2021-10-07
JP2014503555A (ja) 2014-02-13
EP4360709A3 (en) 2024-07-03
AU2019202260A1 (en) 2019-04-18
EP4360709A2 (en) 2024-05-01
US11730794B2 (en) 2023-08-22
JP2024001190A (ja) 2024-01-09
US20130295094A1 (en) 2013-11-07
US11253572B2 (en) 2022-02-22
US20240123030A1 (en) 2024-04-18
BR112013017752A8 (pt) 2018-01-09
US20210121524A1 (en) 2021-04-29
EP3763379A1 (en) 2021-01-13
US20170202911A1 (en) 2017-07-20
US20180339018A1 (en) 2018-11-29
SG191334A1 (en) 2013-08-30
AU2012205599B2 (en) 2016-10-20
AU2021200935A1 (en) 2021-03-11
MX2013007847A (es) 2013-07-29
US20210308216A1 (en) 2021-10-07
KR20220097542A (ko) 2022-07-07
US9254338B2 (en) 2016-02-09
US10857205B2 (en) 2020-12-08
US11986511B2 (en) 2024-05-21
NZ612593A (en) 2015-03-27
WO2012097019A1 (en) 2012-07-19
SG10201509193UA (en) 2015-12-30
US10888601B2 (en) 2021-01-12
IL295359A (en) 2022-10-01
JP2017061467A (ja) 2017-03-30
JP2019167366A (ja) 2019-10-03
KR20180023015A (ko) 2018-03-06
KR20210030510A (ko) 2021-03-17
US20160101152A1 (en) 2016-04-14
US20210085753A1 (en) 2021-03-25
KR20190049934A (ko) 2019-05-09
US11975045B2 (en) 2024-05-07
US20210023173A1 (en) 2021-01-28
BR112013017752A2 (pt) 2017-08-29
AU2017200290A1 (en) 2017-02-02
MX349901B (es) 2017-08-18
US20190247463A1 (en) 2019-08-15
US20190046609A1 (en) 2019-02-14
KR20140043313A (ko) 2014-04-09
CN103533950A (zh) 2014-01-22
IL260167A (en) 2018-07-31
IL227160B (en) 2019-02-28
JP2021193115A (ja) 2021-12-23
AU2017200290B2 (en) 2019-01-03
EP2663325A1 (en) 2013-11-20
US10130681B2 (en) 2018-11-20
KR20200077622A (ko) 2020-06-30
SG10202111177VA (en) 2021-11-29
AU2012205599A1 (en) 2013-07-18
EP3222285A1 (en) 2017-09-27
MX2021006092A (es) 2022-05-18
US20220273764A1 (en) 2022-09-01
US10828345B2 (en) 2020-11-10
CA2824422A1 (en) 2012-07-19
US11707506B2 (en) 2023-07-25
US11559564B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
IL260167A (en) For the treatment of vegf disorders - use of an agonist for angiogenic eyes
HK1254720A1 (zh) 眼科治療
HK1215375A1 (zh) 阿克曼氏菌用於治療代謝病症的用途
IL233467B (en) Methods for determining whether a patient is likely to respond to treatment with a vegf antagonist
ZA201406400B (en) Eye massage device
EP2841154A4 (en) BLADDER TISSUE MODIFICATION FOR HYPERACTIVE BLADDER TROUBLESHOOTING
EP2895067A4 (en) EVALUATION OF MOBILITY DISORDERS
IL274711A (en) Use of a vegf antagonist to treat angiogenic eye disorders
GB201114212D0 (en) Therapeutic agents
AP2014008011A0 (en) Agents for treating disorders involving modulationof ryanodine receptors
IL228593A0 (en) Treatment of proliferative diseases by a chemoluminescent substance
GB201119401D0 (en) Therapeutic agents
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
HK1210271A1 (en) Ophthalmic devices for delivery of beneficial agents
EP2834188A4 (en) FORMATION OF A CONJUGATED PROTEIN BY ELECTROSTATIC WIRING
EP2673363A4 (en) TREATMENT OF ANGIOGENESIS DISORDERS
EP2722041A4 (en) THERAPEUTIC AGENT FOR ALLERGIC RHINITIS
LT2704747T (lt) Akių lašai, skirti konjuktivochalazės gydymui
GB201118065D0 (en) Treatment of movement disorders
PL395618A1 (pl) Urzadzenie do stabilizacyjnego wzmacniania wlókien miesni
EP2696872A4 (en) TREATMENT OF GLAUCOMA
ES1074678Y (es) Dispositivo de articulacion de un somier
GB201115558D0 (en) Therapeutic agents
GB201110614D0 (en) Therapeutic agents
GB201101128D0 (en) Therapeutic agents